Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
5.30
+1.21 (29.58%)
At close: May 13, 2026, 4:00 PM EDT
5.18
-0.12 (-2.26%)
Pre-market: May 14, 2026, 7:37 AM EDT
Replimune Group Market Cap
Replimune Group has a market cap or net worth of $437.63 million as of May 14, 2026. Its market cap has decreased by -39.48% in one year.
Market Cap
437.63M
Enterprise Value
244.84M
1-Year Change
-39.48%
Ranking
Category
Stock Price
$5.30
Market Cap Chart
Since July 20, 2018, Replimune Group's market cap has decreased from $467.51M to $437.63M, a decrease of -6.39%. That is a compound annual growth rate of -0.84%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 13, 2026 | 437.63M | -42.60% |
| Dec 31, 2025 | 762.47M | -18.18% |
| Dec 31, 2024 | 931.93M | 87.18% |
| Dec 29, 2023 | 497.87M | -67.63% |
| Dec 30, 2022 | 1.54B | 21.04% |
| Dec 31, 2021 | 1.27B | -27.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Jul 20, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| C4 Therapeutics | 349.27M |
| Neumora Therapeutics | 347.11M |
| Rezolute | 342.78M |
| Greenwich LifeSciences | 342.35M |
| DiaMedica Therapeutics | 340.54M |
| Compass Therapeutics | 336.76M |
| Immuneering | 335.13M |
| Lineage Cell Therapeutics | 331.57M |